Zdrowie i gospodarka · 20/06/2025
FDA Announces Final Guidance for Post-Warning Letter Meetings Under GDUFA
The FDA has released a final guidance for industry on implementing post-warning letter meetings for certain drug manufacturing facilities, as part of the Generic Drug User Fee Amendments (GDUFA) reauthorization.